Please use this identifier to cite or link to this item:
Title: Antibody-Drug Conjugates for Cancer Therapy.
Austin Authors: Hafeez, Umbreen ;Parakh, Sagun ;Gan, Hui K ;Scott, Andrew M 
Affiliation: Molecular Imaging and Therapy
Medical Oncology
Olivia Newton-John Cancer Wellness and Research Centre
Olivia Newton-John Cancer Research Institute
School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia
Department of Medicine, University of Melbourne, Melbourne, VIC 3084, Australia
Issue Date: 16-Oct-2020
Date: 2020-10-16
Publication information: Molecules 2020; 25(20): E4764
Abstract: Antibody-drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.
DOI: 10.3390/molecules25204764
ORCID: 0000-0003-3891-2489
Journal: Molecules
PubMed URL: 33081383
Type: Journal Article
Subjects: ADC
antibody–drug conjugate
cytotoxic payload
linkers, cancer
molecular imaging.
monoclonal antibody
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 16, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.